RxDoctor Payments Data

Judith Pickett, MD

Family Medicine · Munster, INNPI 1467699041

Payments from drug & device makers

$5,137in general payments, 2019–2025

Across 172 payments — averaging $29.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$885
  • Novo Nordisk$819
  • Boehringer Ingelheim$806
  • Amgen$462
  • Abbott$384
  • Johnson & Johnson$248
  • plus $2K from 15 others

What the payments were for

  • Food & beverage$5,137100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,137 in reported general payments places this provider in the 85th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$61,834
Medicare patients
246
Services billed
622

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin82$93,362
JanuviaSitagliptin Phosphate64$60,109
OzempicSemaglutide36$37,399
LinzessLinaclotide15$20,190
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$16,742
EliquisApixaban16$15,650
MounjaroTirzepatide12$12,642
TradjentaLinagliptin13$10,235
Incruse ElliptaUmeclidinium Bromide14$7,673
SteglatroErtugliflozin Pidolate11$3,691
Atorvastatin Calcium498$3,072
SynthroidLevothyroxine Sodium39$2,660
Albuterol Sulfate HfaAlbuterol Sulfate105$2,363
Amlodipine Besylate478$2,298
Levothyroxine Sodium201$1,839

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$806$103,59795 claims
MerckJanuvia, Steglatro$152$63,80075 claims
Novo NordiskOzempic$819$37,39936 claims
GSKTrelegy Ellipta, Incruse Ellipta$109$24,41536 claims
AbbVieLinzess, Synthroid$30$22,85054 claims
PfizerEliquis, Dilantin$92$17,39130 claims
Lilly USA, LLCMounjaro$124$12,64212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Munster

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →